OverviewSuggest Edit

Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The company is developing a portfolio of drug candidates with multiple mechanisms of action that will result in a combination therapy to cure HBV.
Arbutus Biopharma seeks to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence.
TypePublic
Founded1992
HQBurnaby, CA
Websitearbutusbio.com
Employee Ratings2.8

Latest Updates

Employees (est.) (Dec 2018)79(-39%)
Job Openings1
Revenue (FY, 2018)$5.9 M(-44%)
Share Price (May 2019)$2.3 (-1%)

Arbutus Biopharma Office Locations

Arbutus Biopharma has offices in Burnaby and Warminster
Burnaby, CA (HQ)
100 - 8900 Glenlyon Parkway
Warminster, US
701 Veterans Way
Show all (2)

Arbutus Biopharma Financials and Metrics

Arbutus Biopharma Revenue

Arbutus Biopharma's revenue was reported to be $5.95 m in FY, 2018
USD

Revenue (FY, 2018)

5.9m

Net income (FY, 2018)

(57.1m)

EBIT (FY, 2018)

(89.8m)

Market capitalization (21-May-2019)

135.2m

Closing stock price (21-May-2019)

2.3

Cash (31-Dec-2018)

36.9m
Arbutus Biopharma's current market capitalization is $135.2 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

15.5m23.3m1.5m10.7m5.9m

Revenue growth, %

(94%)618%

General and administrative expense

5.5m26.4m39.4m16.1m16.0m

R&D expense

51.5m61.3m62.7m57.9m
Quarterly
USDQ1, 2014Q3, 2014Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018

Revenue

4.4m4.4m3.4m603.0k309.0k774.0k235.0k1.0m6.9m1.2m1.6m

General and administrative expense

2.1m1.8m7.7m7.2m23.8m3.7m4.3m4.6m3.7m3.8m2.6m

Operating expense total

10.4m11.2m17.9m20.6m195.6m19.7m18.5m20.5m19.8m23.3m34.0m

EBIT

(6.0m)(6.8m)(14.4m)(20.0m)(195.2m)(19.0m)(18.3m)(19.5m)(12.9m)(22.0m)(32.4m)
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Cash

68.7m166.8m23.4m54.3m36.9m

Accounts Receivable

116.6k1.0m273.0k402.0k1.4m

Prepaid Expenses

1.2m1.3m2.1m

Current Assets

70.3m183.9m132.6m129.4m129.2m
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(62.7m)(384.2m)(84.4m)(57.1m)

Depreciation and Amortization

612.8k589.0k1.1m2.0m2.2m

Accounts Payable

130.0k(2.5m)26.0k736.0k(1.3m)

Cash From Operating Activities

(56.4m)(57.9m)(48.6m)(67.9m)
Quarterly
USDQ1, 2014Q3, 2014Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018

Net Income

(14.9m)(15.9m)(145.9m)(19.6m)(18.6m)(36.9m)(11.6m)

Depreciation and Amortization

134.0k133.0k147.0k217.0k469.0k291.0k334.0k814.0k593.0k1.2m1.7m

Accounts Payable

1.1m2.4m(7.4m)(1.1m)(1.1m)(887.0k)(3.9m)(1.7m)(1.8m)(3.3m)(2.2m)

Cash From Operating Activities

9.2m(6.7m)(16.7m)(11.5m)(28.4m)(14.7m)(17.5m)(22.6m)(15.7m)(37.6m)(50.8m)
USDY, 2018

Revenue/Employee

75.3k

Financial Leverage

1.1 x
Show all financial metrics

Arbutus Biopharma Revenue Breakdown

Embed Graph

Arbutus Biopharma revenue breakdown by business segment: 6.4% from Collaborations and Contracts and 93.6% from Licensing Fees, Milestone and Royalty Payments

Arbutus Biopharma Blogs

Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives

Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives Content Import Thu, 03/07/2019 - 16:04 Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments a…

Arbutus to Present at Cowen Health Care Conference

WARMINSTER, Pa. , March 04, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray , Arbutus’ President and CEO, will present a corporate overview and business update at

Arbutus to Report Fourth Quarter and Year-End 2018 Financial Results and Provide Corporate Update

WARMINSTER, Pa. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcast, for

Frank Torti MD

Frank Torti MD jo-en.bautista… Mon, 11/26/2018 - 17:22 Frank Torti MD Chairman For much of his career, Dr. Torti was a partner at New Enterprise Associates (NEA), a leading venture capital firm. At NEA, Dr. Torti managed early and growth-stage investments in numer…

Arbutus to Report Third Quarter 2018 Financial Results

Arbutus to Report Third Quarter 2018 Financial Results johncarlo.ong@… Wed, 10/31/2018 - 08:33 Arbutus to Report Third Quarter 2018 Financial Results Oct 31,2018 This release is a backfill from a News Wire General WARMINSTER, Pa., Oct…

Arbutus Names New Members to its Board of Directors

Arbutus Names New Members to its Board of Directors Content Import Mon, 10/22/2018 - 08:34 Arbutus Names New Members to its Board of Directors Oct 22,2018 This release is a backfill from a News Wire General WARMINSTER, Pa., Oct. 22, …
Show more

Arbutus Biopharma Frequently Asked Questions

  • When was Arbutus Biopharma founded?

    Arbutus Biopharma was founded in 1992.

  • How many employees does Arbutus Biopharma have?

    Arbutus Biopharma has 79 employees.

  • What is Arbutus Biopharma revenue?

    Latest Arbutus Biopharma annual revenue is $5.9 m.

  • What is Arbutus Biopharma revenue per employee?

    Latest Arbutus Biopharma revenue per employee is $75.3 k.

  • Who are Arbutus Biopharma competitors?

    Competitors of Arbutus Biopharma include Rani Therapeutics, ZIOPHARM Oncology and Syros Pharmaceuticals.

  • Where is Arbutus Biopharma headquarters?

    Arbutus Biopharma headquarters is located at 100 - 8900 Glenlyon Parkway, Burnaby.

  • Where are Arbutus Biopharma offices?

    Arbutus Biopharma has offices in Burnaby and Warminster.

  • How many offices does Arbutus Biopharma have?

    Arbutus Biopharma has 2 offices.